AUSTRALIA Patents Act 1990 COMPLETE SPECIFICATION Standard Patent Applicant: BIOPHORETIC THERAPEUTIC SYSTEMS, LLC Invention Title: FINGER-MOUNTED ELECTROKINETIC DELIVERY SYSTEM FOR SELF ADMINISTRATION OF MEDICAMENTS The following statement is a full description of this invention, including the best method for performing it known to us: - 2 FINGER-MOUNTED ELECTROKINETIC DELIVERY SYSTEM FOR SELF ADMINISTRATION OF MEDICAMENTS RELATED APPLICATIONS 5 This application is a divisional of Australian Patent Application No. 2003234691. BACKGROUND OF THE INVENTION 10 The present invention relates generally to the electrokinetic mass transfer of substances into and/or extracting substances from tissue and particularly to apparatus for extracting, e.g., body fluids and/or harmful 15 substances from a site, and/or delivering substances, e.g., a medicament to a treatment site. Electrokinetic delivery of medicaments for applying medication locally through an individual's skin is known. 20 One type of electrokinetic delivery mechanism is iontophoresis, i.e., the application of an electric field to the skin to enhance the skin's permeability and to deliver various ionic agents, e.g., ions of soluble salts or other drugs. In certain situations, iontophoretic 25 transdermal or transmucocutaneous delivery techniques have obviated the need for hypodermic injection for many medicaments, thereby eliminating the concomitant problem of trauma, pain and risk of infection to the individual. Other types of electrokinetic delivery mechanisms include 30 electroosmosis, electroporation, electromigration, electrophoresis and endosmose, any or all of which are generally known as electrotransport, electromolecular transport or iontophoretic methods. The electrokinetic delivery mechanism may also be accompanied by ultrasonic 35 vibration to further facilitate electrokinetic transport of the substance, e.g., by opening pathways in the skin. Ultrasound may be employed in a number of ways such as (i) N \Melboune\Cases\Patent\54000-54999\P54475 AU \Specis\P54475 AU I Specification 2007-6-29.doc 1/08/07 - 3 traditional piezoelectric elements, (ii) magnetostrictive alloys, (iii) Application Specific Integrated Circuits (ASICs) with an ultrasound transmitter built in or (iv) by thin foil sheets with incorporated piezoelectric dipole 5 elements. See, for example, U.S. patent application Serial No. 09/205,751, filed December 4, 1998, of common assignee herewith, the disclosure of which is incorporated herein by reference. io There are several difficulties with electrokinetic delivery of substances such as medicaments. One is the heretofore need for somewhat cumbersome, bulky and costly equipment which oftentimes requires the presence of an individual at a doctor's office or treatment centre and 15 use of medical professionals to administer the medicament. Private, self-administration of medicaments or for diagnostic application by the individual at non-medical or non-professional facilities is highly desirable. Also, an easily transportable apparatus for electrokinetic delivery 20 of medication, for example, a lightweight, compact portable device useful with an applicator packaged as a single or unit dosage applicator, and which may be readily and easily manipulated to contact the treatment site appears ideal as a patient/consumer friendly self 25 administration system appropriate for many circumstances. BRIEF DESCRIPTION OF THE INVENTION The present invention provides an electrokinetic delivery 30 system for personal use in self-administration of a medicament to a treatment site on an individual, comprising: a device having a generally ring-shaped body and a through-opening for receiving and releasably retaining 35 the device on the finger of the individual; a self-contained power source carried by said device; N \Meibourc\Cases\Patcnt\54000-54999\P54475 AU. I\Specis\P54475 AU. I Specificaion 2007-6-29 doc 1/08/07 - 4 a first electrode carried by said device in electrical contact with said power source; a second electrode carried by said device for electrical contact with a portion of the individual's s body, said second electrode being in electrical contact with said power source whereby, upon application of said first electrode to a treatment site with the medicament interposed between the first electrode and the treatment site and completion of an electrical circuit through the 10 first electrode, the medicament or conductive carrier therefor, the treatment site, the individual's body, said second electrode and said power source, said device causes an electrical current to flow for electrokinetically driving the medicament into the treatment site. 15 BRIEF DESCRIPTION OF THE DRAWINGS FIGURE 1 is a schematic representation of a manner of applying an electrokinetic delivery device according to a 20 preferred embodiment of the present invention, as disclosed in this and the parent application 2003234691, to a treatment site; FIGURE 2 is an enlarged fragmentary exploded perspective 25 view illustrating the device hereof; FIGURE 3 is a perspective view of a preferred embodiment of the device as viewed from its underside; 30 FIGURE 4 is an elevational view of the device at a proximal end thereof; FIGURE 5 is a top plan view of the device; 35 FIGURE 6 is a side elevational view thereof; N \Melbourne\Cases\Patent\54000-54999\P54475.AU I\Specis\P54475 AU I Specification 2007-6-29 doc 1/08/07 - 5 FIGURE 7 is an exploded perspective view of a medicated cartridge and the application head to which the cartridge is applied; 5 FIGURE 8 is a side elevational view of a portion of an applicator head and substrate in accordance with another embodiment hereof; FIGURES 9 and 10 are disassembled and assembled io perspective views of an electrokinetic delivery device according to another embodiment hereof; FIGURE 11 is a block diagram of an example electrical circuit for the device hereof; 15 FIGURE 12 is a schematic of an example electrical circuit for the device hereof; FIGURE 13 is a perspective view of a face mask 20 electrokinetic delivery device according to a further preferred embodiment hereof; FIGURE 14 is a view similar to Figure 13 illustrating a further form of face mask; 25 FIGURE 15 is a side elevational view of a generally ring shaped electrokinetic delivery device according to a still further preferred embodiment; 30 FIGURE 16 is a perspective view thereof; FIGURES 17 and 18 are a bottom view and a side perspective view, respectively, of a patch applicator; and 35 FIGURES 19A and 19B are flow charts illustrating an example operation of the device of FIGURE 2. N \Melboumc\Cases\Patent\S4000-54999\P54475 AU I\Specis\P54475 AU I Specification 2007-6-29.doc 1/08107 - 6 DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT OF THE INVENTION Referring now to the drawing figures, particularly to 5 Figure 1, there is illustrated a portable, self-contained, lightweight, compact, finger-mounted, electrokinetic medicament-delivery device or medicator, generally indicated 10 applied to a treatment site on an individual. The device 10 includes a housing 12 mountable to an 1o individual's finger, for example, by straps 14, with a tip 16 of the device 10 mounting an active electrode for -driving, i.e., electrokinetically transporting, medicament interposed between the active electrode and the individual's treatment site into the treatment site upon 15 completion of an electrical circuit through the device, the active electrode, the medicament or hydration material carrying the medicament, the individuals body and a counter electrode, i.e., tactile electrode carried by the device. As illustrated, the tip 16 of device 10 housing 20 the active electrode lies adjacent to and underlies the fingerprint portion of the tip of a digit, preferably an index finger, of an individuals hand, enabling the device to be easily manipulated by the individual's arm, hand and finger such that the active electrode at the tip of device 25 10 may be disposed in overlaying relation to a treatment site with the medicament or medicament-carrying substrate interposed therebetween. Referring to Figure 2, the device 10 is preferably 30 provided in two parts: a first part or proximal portion 20 and a second part or distal portion 22. It will be appreciated that the device 10 is substantially rigid in construction, is preferably formed of a plastic material, although other materials may be utilized, and, while a 35 two-part device is preferred, a unitary device or a device formed of more than two parts may be provided. Additionally, while the two parts, when assembled, provide N \Melboume\Cases\Patent\54000-54999\P54475.AU. I\Specis\P54475 AU. I Specification 2007-6-29.doc 1/08/07 - 7 a substantially rigid device, the parts may be interconnected by flexible portions, enabling the device to flex with the flexing of the individual's finger. As explained below, the proximal and distal portions 20 and 5 22 are connected together to form part of an electrical circuit between an active electrode carried by the distal portion 22, and a power source, tactile electrode and other electronics carried by the proximal portion 20. 10 The proximal portion 20 includes a compartment 24 for receiving a power source 25, e.g., a 1.5 volt silver oxide battery, as well as an electronics pod 26 for carrying the electronics described below. The compartment 24 may include a removable cover 28 affording access within the 15 compartment. Preferably, however, the compartment is sealed. Proximal portion 20 is elongated and shaped and configured to overlie a portion of an individual's finger, preferably 20 an index finger, along opposite sides of the first finger joint, as best illustrated in Figure 1. That is, forward and rear portions 30 and 32, respectively, of the proximal portion 20 are slightly angled relative to one another to straddle the first finger joint (the joint between the 25 first and second phalanges of a digit) at the apex of the forward and rear portions 30 and 32. Also, the proximal portion 20 has a concave surface along its underside, as best illustrated in Figure 3, to comfortably overlie and substantially conform to the outer convex portions of the 30 individual's finger on opposite sides of the first finger joint. Adjacent one side and along a margin of proximal portion 20, there are provided a pair of laterally projecting loops 34. Along the opposite margin of proximal portion 20, there are provided a pair of tabs 36. Straps 35 14 (Figure 1) are secured in the loops 34. The opposite ends of the straps have one of hook-and-loop fasteners, while the outer surfaces of the tabs 36 carry the other of N \Melboume\Cases\Patent\54000-54999\P54475.AU \Specis\P54475.AU I Specification 2007-6-29.doc 1/08/07 - 8 hook-and-loop fasteners (Velcro*) , thereby enabling the device 10 to be releasably secured to an individual's finger. Other means for releasably securing the proximal portion 20 to the individual's finger may be provided. For 5 example, one or more rings or sleeves may be mounted directly to the proximal portion 30 for receiving the individual's finger. Arcuate sections may project from opposite sides of the proximal portion 30 to form one or more resilient split rings for engaging along opposite 10 sides of the individual's finger, their distal ends being spaced from one another along the inside surface of the individual's finger. Elastic straps, buckle-type fasteners, and snap fasteners on elastic or flexible straps may also be utilized. Other types of releasable 15 securements will be apparent to those of skill in this art. The distal portion 22 of device 10 includes a generally frustoconical section 40 (Figure 2) sized and configured 20 to receive the tip of an individual's finger, the smaller diameter end of section 40 forming an opening 41 and comprising the outer end of the device. The distal portion 22 may include a closed annular ring as illustrated or a split ring. However, an open-ended frustoconical section 25 having a frustoconical interior surface is preferred because it affords greater control and stability to the active electrode when the medicator is manipulated by the individual to engage the treatment site. Also, the smaller end 41 of the frustoconical section 40 is open to enable 30 the individual's fingertip, including the tip of the individual's nail, to project from the device. It will be appreciated, however, that distal portion 22 may be extended and closed if desired. As illustrated in Figure 2, a pair of electrical contacts 42 project from the 35 distal portion 22 for engagement in mating electrical sockets 44 formed on the distal end of the proximal portion 20. Thus, when the distal and proximal portions N:\Melbourne\Cases\Patent\540O0-54999\P54475.AU. I\Specis\P54475.AU I Specification 2007-6-29.doc 1/08/07 - 9 are secured to one another, the power source and electronics of the proximal portion are electrically connected with the active electrode and a counter electrode 60 carried by the distal portion 22. Note also 5 that the juncture of the proximal and distal portions 20 and 22, respectively, lies adjacent the second joint between the second and third phalanges of the digit leaving the third phalange of the digit for reception within the frustoconical interior of the distal portion 10 22. Referring to Figures 3-6, preferably a circular annular housing 50 is provided along the underside of the distal portion 22 and forms part of an applicator head 51 of the is distal portion 22. Housing 50 includes an active electrode 54, preferably in the form of a metal disk, mounted at the base of a circular recess 52 (Figure 6) in housing 50. The active electrode 54 is in electrical contact with the power supply and electronics in the proximal portion 20 20 when the portions 20 and 22 are connected one with the other. Particularly, a spring 55 in housing 50 interconnects the active electrode 54 and electrical connections 57 within the distal portion 22 in electrical contact with contacts 42 (Figure 2) . As illustrated in 25 Figure 6, a substrate 56 is disposed in the recess 52, and is preferably formed of a porous, open-cellular, inert material. The substrate material may comprise a non-woven fabric manufactured by Cerex of Pensacola, Florida, identified as Type DN, Group DN07 & DN15. Other suitable 30 types of materials may also be used, provided those materials, at least in the portion of the substrate through which the medicament will be transported to the treatment site, constitute a minimum barrier to the electrokinetic transfer of medicament molecules from the 35 substrate to the treatment site. The substrate 56 preferably conforms to the shape of recess 52, e.g., substantially circular, and maybe frictionally maintained N.\Melbourne\Cases\Patent\54000-54999\PS4475.AU I\Specis\PS4475.AU I Spcification 2007-6-29doc 1/08/07 - 10 within the housing and bearing- against active electrode 54. Alternatively, other means may be provided to secure the medicament containing substrate to the housing 50. For example, the recess 52 may include an inwardly directed s flange or lip for retaining a substrate within the recess. A preferred embodiment for releasably securing the substrate in the recess 52 in electrical contact with the active electrode 54 is described below with reference to Figure 7. 10 It will be appreciated that the substrate 56 may be provided to the user with or without medicament. Thus, when using the finger splint medicator hereof, the user may apply the medicament to the substrate such that the 15 medicament lies within or wicks into the interstices of the material of the substrate. If the applied medicament is not per se conductive, the substrate may also be hydrated by the application of water, for example, by using an eyedropper. In the preferred form, however, a 20 unit dose of the medicament is supplied with and pre packaged in the substrate 56. The medicament permeates the interstices of the porous substrate 56 and the substrate with the medicament is disposed within the recess 52 of the distal portion 22 of the device 10 and factory-sealed. 25 For example, as illustrated in Figure 7, a retainer ring 59 may overlie the substrate 56 and a release film, e.g., a foil lid 63 having a finger pull or tab 65, may overlie the substrate 56 exposed through the end of the retainer ring 59. By removing the lid 63 prior to use, the 30 medicament permeated in the substrate is exposed for electrokinetic transport into the treatment site. Alternatively, a unit dose of the medicament may be pre filled and contained within a rupturable polymer reservoir 35 or capsule within the substrate 56 as in U.S. Patent No. 5,676,648, issued October 14, 1997, the disclosure of which is incorporated herein by reference. By N \Melboume\Cases\Patent\54000-54999\P54475.AUI\Specis\PS4475.AU.j Specification 2007-6-29 doc 1/08/07 - 11 encapsulating the medicament in a rupturable reservoir or sealing a medicament-permeated substrate, whether within device 10 or separate therefrom, a long shelf-life is assured for medicaments. A non-pre-filled substrate may 5 also be provided the user with the medicament provided separately. In that instance, the user may apply the substrate to the distal portion 22 (if not already contained within housing 50) and either apply the medicament to the substrate before application of the lo device to the treatment site or interpose the medicament between a suitably hydrated substrate (if auxiliary hydration is required) and the treatment site whereby electrokinetic transport of the medicament into the treatment site can be accomplished. To use the substrate 15 with the encapsulated medicament, the capsule(s) can be opened, for example by peel-away means, such as peeling away a release film, or ruptured by applying pressure to the substrate, for example, by pressing the substrate toward the active electrode 54 after the substrate has 20 been located within the recess 52 of the applicator head either upon manufacture or by the user. By rupturing the capsules, the medicament permeates the interstices of the substrate. If the medicament requires hydration to afford electromotive transport into the treatment site upon 25 application of the electric current, the user may hydrate the pad similarly as previously described. Alternatively, an additional one or more capsules containing hydrating or conductive material, e.g., water or saline, and/or another formulation excipient(s) such as sodium lauryl sulfate 30 with or without cetostearyl alcohol may be pre-packaged within the medicament and or substrate. The substrate 56 is intended for single use only. That is, once the medicament has been electrokinetically driven 35 from the substrate into the treatment site, the distal portion 22 is disconnected from the proximal portion 20 and discarded without the consumer/patient touching the N \Mclboume\Cases\Patent\54000.54999\PS4475.AU. I\Specis\PS4475 AU I Specifcation 2007.6-29.doc 1/08/07 - 12 medicament or substrate. It is important to prevent reuse of the distal portion and its used substrate and to render it disposable. For example, active disease particles or other biologic material on the substrate could cause 5 cross-contamination if reused. Insufficient dosage, dehydration or degradation of the medicament could occur if reused. Physical separation of the substrate from the active electrode could occur, rendering dosage or even operability problematical upon reuse. Alternatively, the 10 substrate 56 may be removed from the applicator head 51 and discarded and a new substrate applied to the applicator head. Where the medicament is pre-packaged with the substrate either by permeation within the substrate with a release film or foil seal or within a releasable or 15 rupturable capsule within or near the substrate, a colouring agent can be employed, such as iodine, which turns colour upon contact with starch in the open-cell material to visibly indicate that a unit dose of medicament has been used. Other types of colouring agents 20 can be used to indicate usage of the applicator, e.g., pH indicators, wet saturation indicators or oxidisable pigments. Referring to Figure 6, it will be appreciated that the 25 device 10 is generally elongated and extends generally parallel to the individual's finger 71 when in an extended position as illustrated. The housing 50 extends at an angle relative to the direction of elongation represented by a centreline 73 in Figure 6 of the device which 30 generally parallels central portions of the individual's finger when extended. Thus, the outer planar face of the active electrode 54 extends at the same angle as the housing relative to the elongated device and faces outwardly and away from the device and the individual's 35 finger. The angle at an intersection between the direction of elongation (centreline 73) and a line through the planar surface of the active electrode 54 is an obtuse N \Melbourne\Cas\Patent\54000-54999\P54475.AU \Specis\P54475.AU I Specification 2007-6-29.doc 1/08/07 - 13 angle of approximately 1600 but may lie within a range of about 100*-185*. The angular direction of the active electrode relative to the device 10 facilitates application of the device to treatment sites variously 5 located about an individual's body. Reverting to Figure 2 and in a preferred embodiment, the counter electrode 60 is located in the distal portion 22 on the bottom of the interior frustoconical surface. 10 Counter electrode 60 may be covered with a conductive material, e.g., water or hydrogel, to facilitate electrical contact with the underside of the individual's fingertip. The counter electrode 60 is electrically insulated from the active electrode. The counter 15 electrode 60 is electrically coupled to the terminal of the battery opposite the battery terminal to which the active electrode 54 is coupled when the distal and proximal portions are electrically interconnected with one another. It will be appreciated that by locating the 20 counter electrode 60 along the inside surface of the distal portion, the act of inserting the individual's fingertip into the opening in the distal portion ensures good electrical contact between the counter electrode and the individual's finger. Alternatively, the counter 25 electrode may be exposed along the underside of the proximal portion 20 for engagement with the individual's finger upon the individual donning the finger splint medicator. In a further alternative, the counter electrode may be located along the underside of both the proximal 30 and distal portions 20 and 22, respectively. Thus, a full-length portion of the individual's finger on opposite sides of the first finger joint and including the fingertip may be in contact with the counter electrode, in either case, affording a good electroconductive contact 35 therewith. N \Melboume\Cascs\Patent\54000-54999\PS4475 AU I \Specis\P54475 AU I Specification 2007-6-29doc 1/08/07 - 14 Referring to Figure 8, there is illustrated a portion of an applicator head 51a in conjunction with a substrate 56a separate and apart from the device per se. The applicator head 51a is similar to the applicator head 51, except that 5 the active electrode 54a forms a circular projection from the applicator head 51a, Also illustrated in Figure 8 is a substrate 56a which has been removed from a package, not shown, and which substrate contains the medicament. With the substrate 56a containing the medicament interposed 10 between the active electrode 54a and the treatment site T.S., it will be appreciated that upon completing the electrical circuit by coupling the distal and proximal portions to one another, the medicament in the substrate may be electrokinetically motivated into the treatment 15 site. As a further alternative, the medicament can be applied by a user directly to the treatment site or to a non-prefilled substrate, together with any necessary hydration material, and the circuit completed by applying the active electrode 54a to the medicament or medicament 20 containing substrate. The first three stages of Herpes I and II are prodromal, erythema and papule/edema. The preferred treatment with Acyclovir* is to identify and treat the infection in its 25 prodromal stage (no visible signs or symptoms, but individuals feel a tingle or burning or some sensation in the area that breaks out later), i.e., treat optimally with least amount of medicament and shortest application time. Erythema is second (still quite early, with some 30 redness and/or swelling) and is the preferred stage to start treatment if prodromal stage is missed. Papule or edema stage still responds to treatment but not as quickly (skin damage has started to occur with small sores which may be barely visible). 35 In a preferred form of the present invention, particularly for the treatment of Herpes I and II-type infections, N Welboume\Cases\Patent\54000-54999\P54475 AU I\Specis\P54475 AU I Specification 2007-6-29 doc 1/08/07 - 15 Acyclovir* is the medicament of choice. Acyclovir* may be provided in a cream formulation with approximately 5% comprising the drug Acyclovir*. For example, a 250 milligram formulation of topical cream containing 12.5 5 milligrams of Acyclovir*, i.e., a 5% formulation, may be utilized. Significantly, this relatively small amount of medicament in the formulation, when applied electrokinetically over a predetermined time duration, affords a therapeutically effective dose. The dosage and 10 time of application may be varied. For example, an approximate 2% formulation of about 4 to 5 milligrams of the active medicament (e.g., Acyclovir*) in a 250 milligram cream formulation applied electrokinetically over a period of no greater than fifteen minutes or an 15 approximate 14-15% formulation, e.g., 37 milligrams in a 250 milligram cream and Acyclovir® formulation, applied electrokinetically for approximately three minutes is believed therapeutically effective. Percentage formulations between 2%-15% over time durations between 20 fifteen minutes and three minutes are believed also to be therapeutically effective. For example, 8%-10% formulations over 5-6 minutes' time duration are also believed therapeutically effective. Thus, using the present device and a small amount of the active medicament 25 applied electrokinetically and locally via the present delivery system has been found effective. While a cream formulation is preferred, it will be appreciated that the topical base may also be a liquid, gel, ointment or lotion. 30 The formulation for the medicament may also comprise an oil, water, or a combination oil and water, to facilitate penetration of the skin as the excipient(s). For example, oil facilitates penetration of the stratum corneum layer 35 of the skin, while water facilitates penetration of the basal epidermal layer. Thus, a combination of the drug with oil and water included in the formulation is N \Melboune\Cases\Patent\4000-54999\P54475 AU \Specis\P54475 AU I Specification 2007-6-29.doc 1108/07 - 16 preferred to facilitate penetration of the drug to the treatment site. In a further formulation of Acyclovir*, solvents such as methylene chloride or beta-cyclodextrin may be included to improve water solubility and stability. 5 The foregoing treatment is also effective for treating Herpes Zoster, Cytomegalovirus (CMV) and additional medicaments of choice may include foscarnet and gancilovir. The device and methods hereof may also be used 10 to provide electrokinetic transport, with or without ultrasound, for tamoxifen citrate, i.e., an antiestrogen, to inhibit Trans Growth Factor P-1 (TGFP-l) to suppress estrogen receptors to aid in wound healing and treatment of keloid scar tissue. Also, treatment of eczema with 15 tacrolimus or pimecrolimus as a stand-alone therapy or with steroids is effective. Still further, while Acyclovir* acts on the polymerase enzyme, drug formulations which act on the helicase-primase enzyme are also effective for treating Herpes I and II. 20 Referring now to Figures 9 and 10, there is illustrated a further form of an electrokinetic delivery device according to a preferred embodiment of the present invention wherein like reference numerals are applied to 25 like parts, preceded by the numeral 1. In this form, the device 110 includes proximal and distal portions 120 and 122, respectively, and contacts 142 and 144 in the distal and proximal portions, respectively; for completing the electrical circuit as described herein. The proximal 30 portion 120 includes loops 134 and tabs 136 on opposite sides for securing a strap to the proximal portion and securement of the device to the individual's finger. The proximal portion 120 houses the electronics and power source similarly as the proximal portion 20. 35 The distal portion 122 is generally frustoconically shaped, as is the distal portion 22 of the prior N \Melboune\Cases\Patent\54000-54999\P54475 AU. I\Specis\P54475 AU.A Specification 2007-6-29 doc 1/08/07 - 17 embodiment, and mounts a pylon or a pair of pylons 123 interconnecting the frustoconical section 124 and the applicator head 151 housing the substrate. The distal portion 122 also carries the counter electrode 160 which, 5 upon interconnection of the proximal and distal portions is electrically connected to the power source and electronics of the proximal portion 120. It will be appreciated that the undersurface of the proximal portion 120 is concave and angled to accommodate the first finger 10 joint and opposite sides thereof for mounting the proximal portion on the individual's finger. Similarly, the distal portion 122 has a frustoconical interior surface for receiving the fingertip of the individual upon electrical and mechanical connection of the proximal and distal 15 portions to one another. In Figure 10, the device is illustrated in an operable condition applied to an individual's finger, with the individual's fingertip projecting into the distal portion and in electrical contact with the counter electrode 160. 20 Figure 11 illustrates a block diagram of representative electrical circuitry 200 for use in the finger splint medicator. Electrical circuitry 200 includes an on/off flag 202, a power on/off switch 204, a power source 206, a 25 switching regulator 208, processing circuitry (microprocessor) 210, a variable voltage source 212, a current clamp 214, electrostatic discharge (ESD) protection circuits 216, a current transducer 218, and light emitting diode or diodes (LED's) 220. The on/off 30 flag 202 is built into the distal portion and may simply include a conducting "flag" surface which completes a circuit of the power on/off switch 204 upon engaging to the proximal portion of the finger splint medicator. The flag surface may, for example, be a thin (e.g., 0.032" 35 thick), copper-clad G10 board with copper on one side thereof. The power on/off switch may simply include two N :Melboume\Cases\Patcnt\54000-54999\P54475 AU \Specis\PS4475 AU I Specification 2007-6-29 doc I/08/07 - 18 contacts connecting to the power source 206 and to the remaining parts of electrical circuitry 200. Power source 206 is a battery such as a silver oxide 5 battery having an open-circuit voltage, for example, of 1.55V. The useful life of the battery terminal voltage ranging from 1 to 155 V is insufficient to operate circuit elements and components such as processing circuitry 210 and LED's 220. The low battery voltage is tolerated due to 10 the compensation by switching regulator 208, which converts the unsteady apd decaying battery voltage to a constant value of, for example, 2.7V. Skin and tissue resistance largely controls the bias 15 potential required to sustain the treatment current. Other factors include the conductivity of medicament and the resistance between the skin and counter electrode interfaces. A typical range of overall resistance to be encountered is from 5 kohm to 80 kohm. In the most extreme 20 case, a potential of over 30V may be necessary. Variable voltage source 212 converts the low battery voltage to a suitable high output value controlled by a signal from processing circuitry 210. Measurements of the treatment current from current transducer 218 are compared with a 25 desired treatment current for the particular application to obtain an error signal. Processing circuitry 210 increases or decreases the control signal to the variable voltage source 212 with an appropriate digital output signal to reduce and eliminate the measured error signal 30 so as to obtain the minimal necessary instantaneous bias potential for maintenance of the desired treatment current. Current clamp 214 is a redundant safety device used to limit the treatment current to a safe, maximum value (e.g., 450 microamps) under any circumstances. 35 Electro Static Discharge (ESD) protection circuits 216 (such as one or more diodes) are installed at the entry N \Melboume\Cases\Patent\540O0-54999\P54475AU. I\Specis\P54475 AU. I Specification 2007-6-29 doc 1/08/07 - 19 points of the flag terminal and the positive and negative treatment electrodes, respectively, to protect the internal circuitry from electrostatic damage. The ESD protection circuit for the flag terminal is disposed on 5 the proximal side. Current transducer 218 converts the instantaneous treatment current to an analogue voltage. This voltage is read by the processing circuitry 210 through an internal 10 analogue-to-digital (A/D) converter. This digital signal is compared with the selected treatment current value scalable to the reference input voltage of the A/D converter. A digital servo loop is maintained by the processing circuitry 210 to minimize and/or eliminate the 15 error signal between the instantaneous treatment current signal and the current reference. The output of the servo loop is a digital signal converted by an R/C (Resistor/Capacitor) circuit to an analogue voltage, which is then used to control the variable voltage source 212. 20 Processing circuitry 210 performs various tasks including, but not limited to, timing control, current measurement, digital servo of treatment current through feedback control of the bias potential, and illumination of LED or 25 LED's. Processing circuitry 210 may be implemented, or example, as a microprocessor, microcontroller, an application specific integrated circuit (ASIC), a programmable logic array or some combination thereof. 30 Processing circuitry 210 includes read-only and/or read/write memory. In one example implementation processing circuitry 210 includes a read/write memory such as an EEPROM. The operations of processing circuitry 210 may be implemented in hardware, software and/or firmware. 35 It is desirable, although not necessary, to reduce and replace hardware elements to the extent possible by using a firmware implementation. Data and instructions for N Mielbom \Cas\Patcnt\54000-54999\P54475 AU I\Specis\P54475 AU I Specificaion 2007-6-29doc 1/08/07 - 20 controlling the overall operation of the finger-splint device may be written respectively, to an EEPROM data memory and a flash program memory, and processing circuitry 210 may execute the instructions in response to 5 various signals supplied thereto. These instructions may include instructions for: " monitoring the treatment current and the battery terminal voltage, e providing timing control for various treatment phases 10 including the initial standby period (for example, indicated by a flashing green LED), soft-start period, main treatment period (indicated by a constant green LED) and the final soft stop period (indicated by the red LED) The treatment phases need 15 not be the same for all treatments and these phases may vary in some way depending on what is being treated. All the variables, voltage, current, time, electrode size and shape, and the like must be reconsidered and possibly adjusted, 20 e illuminating the LED(s) to provide information to the user, e exciting a crystal oscillator for accurate timing reference, e resetting a watchdog timer to ensure normal software 25 execution, e performing a self-consistency check on the accuracy of analogue-to-digital converter by measuring the predictable voltage drop across a circuit element (such as an LED) during a short, initial power-up 30 period, and * performing servo control of the treatment current by controlling the bias potential generated by the variable voltage source via an output digital signal. 35 The data stored by the read/write memory within the proximal portion may also include a count indicative of the number of treatment cycles for which the finger-splint N:\Melboume\Cases\Patent\54000-54999\P54475.AU \Specis\P54475.AU. I Specification 2007-6-29.doc 108/07 - 21 device has been used. This count is incremented (or decremented) for each treatment and the device is permanently deactivated after the count reaches a prescribed number indicative of a predetermined number of 5 treatments. For example, a disable flag for disabling processing circuitry 210 may be set in memory when the count on the counter is indicative of the prescribed number of treatments. Alternatively or additionally, various mechanisms for preventing the supply of power to io the electrical components may be used to permanently deactivate the device. For example, processing circuitry 210 could generate a signal to burn a fuse when the count on the counter is indicative of the prescribed number of treatments. Similarly, processing circuitry 210 could 15 generate a signal to deliberately damage a transistor or flip a solid state toggle circuit when the count on the counter is indicative of the prescribed number of treatments, It will be readily apparent that other mechanisms (hardware and/or software) may be used and the 20 invention is not limited in this respect. In another example implementation, the read/write memory may store a total treatment time, which is incremented (or decremented) in accordance with a timer during treatment. 25 When the total treatment time reaches some prescribed total treatment time, the device may be permanently deactivated. Here again, for example, the various hardware and/or software disabling mechanisms described above may be used to permanently deactivate the device. 30 In still another example implementation, the proximal portion may be disabled from use for a predetermined time period after each use whereby the next use can only occur after the predetermined time period has expired. In this 35 case, a disable flag could be set for the predetermined time period and processing circuitry 210 could prevent operation of the proximal portion when this flag is set. N \Melboume\Cases\Patent\54000-54999\PS4475.AU I\Specis\P54475 AU.I Specification 2007-6-29.doc 1/08/07 - 22 Also, the distal portion may be deactivated permanently after a single usage. Here again, various mechanisms for prevention of re-use of the distal portion may be used. 5 For example, processing circuitry 210 could generate a signal to burn a fuse incorporated in the distal portion at the end of a treatment. Similarly, processing circuitry 210 could generate a signal to deliberately damage a transistor or flip a solid state toggle circuit 10 incorporated in the distal portion at the end of a treatment. It will be readily apparent that other mechanisms (hardware and/or software) may be used and the invention is not limited in this respect. 15 Processing circuitry 210 may be programmed with (or have accessible thereto) instructions for a plurality of different types of treatments (e.g., herpes, eczema, acne, boils, blemishes and the like). For example, the desired treatment current, ramp-up/ramp down characteristics and 20 total treatment time for herpes may be different than the desired treatment current, ramp- up/ramp-down characteristics and total treatment time for eczema. The determination of which instructions to use may be based upon a detection (or "recognition") of a particular type 25 of distal portion attached thereto. For example, a distal portion for the treatment of herpes may be configured (either physically or electrically) differently than the distal portion for the treatment of eczema. The configuration of the distal portion is detectable by 30 processing circuitry 210 so that processing circuitry 210 thereafter executes instructions appropriate for the particular type of distal portion connected thereto. In another implementation, the distal portion may be 35 provided with an interface for interfacing to a computer. Such an interface may, for example, be a serial port, a parallel port, a USE port, an IEEE 1394 port, etc. The N.\Melboune\Cases\Patcnt\54000-54999\P54475 AU l\Specis\P54475.AU I Specification 2007-6-29.doc 1/08/07 - 23 interface may take the form of a cradle or docking station into which the distal portion is placed, the cradle or docking station connecting to the computer. The interface to a computer allows the uploading and downloading of data 5 from/to the distal portion. For example, a physician, pharmacist or other health care provider could download to the distal portion instructions appropriate for a particular treatment. Alternatively, an appropriate one of a plurality of different, pre-programmed instruction sets 10 may be selected. Processing circuitry 210 may be programmed to record in memory treatment information (such as the time a treatment took place, the duration of the treatment, the distal portion type connected thereto, etc.). This recorded information may be uploaded to a is database containing treatment records for the user via the computer interface. Assuming appropriate power is available, the distal and/or proximal portion may be provided with additional elements. 20 For example, a small liquid crystal display (LCD) could be provided to the distal or proximal portion to provide a visual output of timing and/or diagnostics. Sound generating circuitry such as a buzzer may also be added to provide aural indications such as warnings, end-of 25 treatment, etc. Figure 12 is a schematic showing details of example electrical circuitry 200. Battery 300 corresponds to power source 206 (Figure 11) and may, for example, have an open 30 circuit voltage of 1.55V and a rated capacity of 200 mAhr. A suitable battery may be, but is not limited to, EPX76 1.5V silver oxide battery (designation: IEC SR44) available from Eveready Battery Co., Inc. Such a battery would provide for about 10 treatment sessions, if each 35 were ten minutes in length. N \Melbourne\Cases\Patent\54000-54999\P54475 AU I\Spccis\PS4475 AU I Specification 2007-6-29 doc 1/08/07 - 24 Components U1, L1, D1, C1 and C2 correspond to switching regulator 208 (Figure 11) for converting the battery voltage to a constant value of, for example, 2.7V. Ul may be, but is not limited to, an NCPl402SN27T1 step-up DC-DC 5 converter (TSOP-5) available from On Semiconductor, Inc. Ll may be, but is not limited to, ELJ-EA470KF, 47 microhenry inductor (SMT-1210) available from Panasonic Industrial Co. D1 may be, but is not limited to, an RB751V40T1 Schottky barrier diode (SOD-32 3 ) available 10 from On Semiconductor Inc . C1 and C2 may be, but are not limited to, a 22 microfarad, 4V tantalum capacitor (A case) and a 47 microfarad, 4V tantalum capacitor (B case), respectively. 15 Component U4 corresponds to processing circuitry 210 and may be, but is not limited to, a PIC16F85 microcontroller (SSOP-20) available from Microchip Technology Inc. Components u2, L2, D2 and C3 function as variable voltage 20 source 212 (Figure 11) for converting the low battery voltage to a high output value. U2 may be, but is not limited to, an S-8324D20MC switching regulator (SOT-23-5) available from Seiko Instruments USA. L2 may be, but is not limited to, an ELJ-EA101KF, 100 microhenry inductor 25 available from Panasonic Industrial Co. D2 may be, but is not limited to, an MBR054OT1 Schottky barrier diode (SOD 123) available from on Semiconductor Inc. C3 may be, but is not limited to, a 1 Microfarad ceramic capacitor (50V, Y5V, SMT-1206). Variable voltage source 212 is controlled 30 in accordance with a signal from processing circuitry 210. Based on measurements of the treatment current, processing circuitry 210 calculates an appropriate digital output signal to obtain an instantaneous bias potential. Component R4 coupled with C4 functions as a simple 35 digital-to-analogue converter. R4 may be, but is not limited to, a 10K ohm, 1% metal film resistor (SMT-0603). N:\Melboume\Cases\Patent\54000-54999\PS4475.AU \Specis\P54475.AU. I Specification 2007-6-29.doc 1/08/07 - 25 C4 may be, but is not limited to, a 0.1 microfarad ceramic capacitor (10V, X7R, SMT-0402). Components U3 and R2 correspond to current clamp 214 5 (Figure 11) and limit the treatment current to a maximum, safe value such as, for example, 450 microamps. U3 may be, but is not limited to, an LM334M current source (SO-8) available from National Semiconductor Corp. R2 may be, but is not limited to, a 150 ohm, 1% metal film resistor 10 (SMT-0603) D3, D7 and D8 correspond to (ESD) protection circuits 216 (Figure 11) and D3 comprises 36 V bi-directional voltage suppressor (TVS), which is installed at the positive 15 electrode. This TVS protects internal circuitry from electrostatic damage. D3 may be, but is not limited to, an SMAJ36CA transient voltage suppressor (SMA) available from Diodes Inc. D7 and D8 may BE, but are not limited to, a PSDO3C 3.3V transient voltage suppressors (SOD-323) 20 available from ProTek Devices. R5 corresponds to current transducer 218 (Figure 11) and converts the treatment current to an analogue voltage, which is further stabilized by C5. R5 may be, but is not 25 limited to, a 4.99 Kohm, 1% metal film resistor (SMT 0603). C5 may be, but IS not limited to, a 0.47 microfarad ceramic capacitor (50V, Z5U, SMT-0805) Green LED D6 and red LED D5 correspond to LEDs 220. 30 Suitable LED's include, but are not limited to, a green diffused LED and a red diffused LED available from American Bright Optoelectronics Corp. (BL-B22131 and BL B4531). Green LED D6 remains on during the entire treatment period. The LED normally requires a current 35 limiting resistor for its operation and the resulting power consumption is quite substantial. As shown in Figure 12, a capacitor C8 switched in accordance with U5 operates N \Melboume\Cases\Patent\54000-54999\P54475 AU. I\Specis\P54475 AU I Specification 2007-6-29 doc 1/08107 - 26 as an efficient current limiting device. The situation with red LED D5 is different in that on the rare occasions when it is illuminated, the treatment current is switched off and resistor R3 and the resulting power consumption 5 can be tolerated. U5 may be, but is not limited to, an Sil905DL dual P-channel MOSFET (SC-70-6) available from Vishay Intertechnology Inc. The electronic circuitry described in connection with 10 Figures 11 and. 12 is operable so that the finger-splint electrokinetic medicator provides a controlled current for electrokinetically transporting medicament into the treatment site and into the underlying tissue area. The disclosed electronic circuitry provides an effective 15 therapeutic for a skin lesion by incorporating the following features: * the treatment current is increased and decreased gradually to avoid any uncomfortable sensation of electrical shock, the rise and fall of current may 20 follow a linear ramp or an exponential curve with a long time constant, (e.g., 10 seconds), e the treatment current per application is accurately controlled by automatic feedback, e.g., maintained at 0.4 milliamperes or less, 25 e an upper limit of the treatment current is imposed by a stand-by redundant circuit element in order to safeguard against servo loop malfunction, " minimal bias potential, dictated largely by patient skin resistance, is always applied in order to 30 minimize power consumption, e ESD protection is implemented for electronic circuitry, e indicator light(s) are provided for low battery conditions, diagnostics, hardware malfunction, low 35 treatment current, and test completion, therapeutic phase N:\Melboume\Cases\Patent\54000-54999\P54475.AU. \Specis\P54475 AU.1 Specification 2007-6-29.doc 1/08107 - 27 * the prescribed treatment time period and automatic test termination are accurately controlled, and * treatment history is monitored and the device is permanently deactivated after reaching a prescribed 5 length of time and/or number of treatments or uses. The circuit described in connection with Figures 11 and 12 provide these identified features. However, the present invention is not intended to be limited to only circuits 10 that provide for all these features. In addition, it will be appreciated that the specific components and the arrangements thereof shown in Figures 11 and 12 are provided by way of example, not limitation. For example, power source 300 may be an adapter for converting power 15 from a conventional wall outlet to power suitable for operation of the finger splint. Alternatively, power source 300 may be a battery that is rechargeable via an adapter connected to a conventional wall outlet. In addition, the electronic circuitry may be adapted to 20 include an alternating current source as described in application Serial No. 09/523,217, filed on March 10, 2000, the contents of which are incorporated herein by reference, including the hybrid multi-channel design. In still other alternative implementations, the power source 25 may be provided in the distal portion or the distal portion may be provided with a power source to supplement the power source in the proximal portion. FIGURES 19A and 19B are flow charts illustrating an 30 example operation of the device 10. At step 502, the distal portion 22 is engaged with the proximal portion 20 and power is turned on at step 504 when flag surface 202 completes the circuit of the power on/off switch 204. Processing circuitry 210 performs a battery test operation 35 (step 506) to determine if the battery is okay. It not, the red LED is flashed for a predetermined period of time (e.g., one minute) (step 508) and the power is then N.\Mclboume\Cases\Patent\54000-54999\P54475 AU. \Specis\P54475 AU I Specifcation 2007-6-29.doc 1/08/07 - 28 switched off (step 510). If the battery is okay, processing circuitry 210 determines whether the number of uses of the proximal portion is less than a prescribed number of uses. If not, the red LED is flashed for a 5 predetermined period of time (step 508) and the power is then switched off (step 510). If the number of uses is less than the prescribed number, the green LED is flashed for a predetermined period of 10 time (e.g., 10 seconds) (steps 514 and 516). Then, processing circuitry 210 begins to ramp up the treatment current (step 518). After the treatment current is ramped up, treatment begins. During treatment, processing circuitry 210 checks to determine whether the current is 15 greater than 360 microamps. If not, the green LED is flashed (step 522) and the processing circuitry proceeds to the battery test operation (step 526). If the current is greater than 360 microarnps, the green LED is kept on (step 524) before proceeding to the battery test 20 operation. If the battery fails the battery test operation, the red LED is flashed for a predetermined period of time (step 508) and then the power is switched off (step 510). If the 25 battery is okay, processing circuitry 210 determines whether the treatment time period (e.g., 10 minutes) has elapsed. If not, control returns to step 520. If the treatment time period has elapsed, the ramp down of the treatment current begins and the green LED is kept on 30 (step 530). When processing circuitry determines that the treatment current has decreased below 50 microamps (step 532), the red LED is turned on (step 534) and kept on for a predetermined period of time (e.g., one minute) (step 536). After this predetermined period of time, the red LED 35 is turned off and the treatment number is incremented (step 538). After a predetermined period of time elapses N \Melbourne\Cases\Patent\54000-54999\P54475.AU \Spccis\P54475 AU I Specification 2007-6-29.doc 1/08/07 - 29 (e.g., 4 hours) (step 540), the power is switched off (step 542) FIGURE 19B shows the treatment current servo loop which is 5 executed almost continuously throughout the treatment. At step 560, the treatment current is sampled and converted from an analogue value to a digital value. At step 562, a determination is made as to whether the sampled treatment current is equal to the reference treatment current for 1o the current treatment. If so, control returns to step 560 where the treatment current is sampled again. If the sampled treatment current is not equal to the reference current at step 562, a determination is made at 15 step 564 as to whether the treatment current is greater than the reference current. If so, the control data output of the processing circuit is decreased and this output is converted from a digital value to an analogue value at step 568. If the treatment is not greater than the 20 reference current, a determination is made at step 570 as to whether the treatment current is less than the reference current. If so, the control data output of the processing circuit is increased and this output is converted from a digital value to an analogue value at 25 step 568. When using the device 10, 110 hereof, the individual may apply the proximal portion 20, 120 in overlying relation to a finger, preferably the index finger, to be used to 30 apply the medicament to the treatment site. Thus, the proximal portion 20, 120 is overlaid outside portions of the individual's finger, straddling opposite sides of the first knuckle joint and secured thereto by straps 14, 114. The substrate 56, 156 is preferably pre-packaged with a 35 unit dose of medicament and supplied within the applicator head of the distal portion 22, 122. If not, the substrate may be applied to the recess 52, 152 of the applicator N:\Melboune\Cases\Patent\54000-54999\P54475 AU l\Specis\P54475 AU I Specification 2007.6-29.doc 1/08/07 - 30 head on the distal portion 22, 122 of device 10, 110 with or without the medicament. Particularly, the substrate 56, 156 may be inserted into the recess 52, 152 such that the medicament or hydration material within the substrate 5 makes electrical contact with the active electrode 54, 154. If the medicament is electrokinetically transportable and contained in the substrate, the device is ready for use upon connecting the distal portion 22, 122 with the proximal portion 20, 120. Alternatively, if the medicament 10 is not permeated within the substrate, the individual may apply the medicament to the substrate or over the treatment site with suitable hydration material being applied as necessary or desired. Alternatively, if the medicament is provided in a releasable or rupturable 15 capsule in the substrate, the individual may apply pressure to the substrate in the applicator head, rupturing the capsule, enabling the medicament from the capsule to permeate through the open interstices of the porous substrate. If the medicament is not 20 iontophoretically transportable, the substrate may be hydrated by applying water or saline to the substrate. Once the medicament is enabled for electrokinetic transport, the frustoconical section 40, 140 of the distal 25 portion 22, 122 may be received about the individual's fingertip and contact made with the proximal portion by interconnecting the contacts 42, 142 and 44, 144. By applying the distal portion 22, 122 to the proximal portion 20, 120 and upon application of the applicator 30 head to the treatment site, the electrical circuit is completed. Thus, the electrical circuit includes the active electrode 54, 154, the medicament or the hydration material used to electrokinetically transport the medicament, the treatment site, the individual's body, a 35 return through the counter electrode, the power source and electronics to the active electrode 54, 154. N \Mclbourne\Cases\Patent\54000-54999\P54475 AU I \Specis\P54475 AU I Specification 2007-6-29.doc 1/08/07 - 31 A treatment program may comprise one or more applications of medicament to a treatment site using the finger splint device described above. For example, a treatment program may comprise five applications of medicament. After each 5 application of medicament, the disposable distal portion is removed from the proximal portion, and a new distal portion is connected to the (re-usable) proximal portion prior to the next application. In some instances, it may be desirable to vary the amount and/or efficacy of the 10 medicament from one application to the next. For example, the amount of medicament used for the first application may be greater than the amount of medicament used for some subsequent application. Thus, a user of the finger splint device may purchase a treatment "package" comprising a 15 plurality of distal portions (e.g., one or more having different amounts of medicament) to be used in a predetermined order. The distal portions may be configured electrically and/or mechanically in a manner that permits the processing circuitry of the proximal portion to detect 20 which distal portion is connected thereto. By way of example, not limitation, the distal portion may include registers readable by the proximal portion. The registers may include information such as, but not limited to, the number of that distal portion in a particular order of use 25 of distal portions. If the processing circuitry is programmed to track the medicament applications (e.g., by incrementing a hardware or software counter as each medicament application is completed), the proximal portion can inform the user (e.g., via the red LED or some other 30 output device such as an LCD if provided) when a wrong distal portion (e.g., an out-of-sequence distal portion) is connected thereto. The detection of the distal portion connected thereto can also be used by the processing circuitry to set a timer fixing an amount of time that 35 must pass before the next medicament application. The proximal portion is disabled to prohibit its use until this time period elapses. N \Melboume\Cases\Ptent\S4000-54999\PS4475.AU.i \Specis\P54475.AU I Specification 2007-6-29doc 1/08/07 - 32 In addition, it will be appreciated that the same proximal portion may be used with more than one type of distal portion. Thus, for example, the proximal portion may be 5 selectively connected to one type of distal portion containing medicament for use in the treatment of herpes or to another type of distal portion containing medicament for use in the treatment of eczema. These distal portions may be configured electrically and/or mechanically so that 10 the processing circuitry of the proximal portion can detect the type of distal portion connected thereto. In response to this detection, the proximal portion can, for example, use operating instructions suitable for a medicament application using the distal portion connected 15 thereto. The processing circuitry of the proximal portion may be programmed with (or have accessible thereto, e.g., via a memory) a plurality of different treatment current 20 profiles (treatment current versus time), wherein the treatment current profile that is actually used depends upon the distal portion connected thereto. For example, in the case in which a treatment program comprises a plurality of applications of medicament, the treatment 25 current profile for the first medicament application may be different than the treatment current profile for the last medicament application. Similarly, the treatment current profile for a herpes treatment program may be different than the treatment current profile for an eczema 30 treatment program. Here again, the distal portions may be configured electrically and/or mechanically (e.g., using registers on the distal portion) in a manner that permits the processing circuitry of the proximal portion to detect which distal portion is connected thereto. In this way, 35 the processing circuitry can use the treatment current profile appropriate for the proximal portion connected thereto. N \Meiboume\Cases\Patent\54000-54999\P54475 AUl \Specis\P54475.AU I Specification 2007-6-29.doc 1/08/07 - 33 Referring now to Figure 13, there is illustrated a further embodiment of a device for electrokinetically transporting a medicament into the skin and is particularly useful for 5 applying medicament over large wide areas of an individual's face. For example, the illustrated mask, generally designated 150, may be used to treat dermatological conditions, e.g., eczema, psoriasis acne, boils, blemishes, provide anesthesia, or to provide dermal 10 exfoliation. Treatment for wrinkles may be accomplished by delivering a modulator of collagen deposition, an organic nitrate, e.g., gallium nitrate. Treatment with metronidazole for rosecea is also beneficial. In this form of the present invention, there may be provided a full 15 face mask 155 (Figure 13) or a partial face mask 154 (Figure 12). The face masks 152 and 154 may be formed of a matrix, e.g., a plastic or fabric material, which may be flexible for providing contact between an underlying medicament-carrying substrate 156. The underlying 20 substrate 156 is formed of a porous material similarly as the substrates previously discussed. The porous material preferably has honeycomb cells which divide the substrate laterally to minimize lateral disbursement of the medicament contained in the substrate. 25 An electrical connector 158 carried by the mask connects an electrical power source to the mask via a plurality of independent or isolated electrical current channels or lead wires 160 carried by the matrix to form individual 30 electrical conductive channels in the matrix. The current flowing through the channels is separately controlled to prevent tunnelling of the current which would adversely affect the user. 35 The face mask is preferably portable, although it will be appreciated that the power supply can be provided either by an adapter plugged into a conventional electrical N:\Melboume\Cases\Patent\54000-54999\P54475.AU l\Spcs\Ps54475.AU I Specification 2007-6-29 doc 1/08/07 - 34 current supply or a "tabletop" or "portable" type unit with batteries that may be either disposable or rechargeable. Preferably, however, the power supply may be disposed in a housing portion 162 which corresponds in 5 functionality to the electronics and power source contained in the proximal portion previously discussed. Additionally, another housing portion 164 is adapted for releasably coupling with the portion 162. As in the prior embodiments, connection of housing portions 162 and 164 10 activates the device. Portions 162 and 164 may serve, in effect, as an on/off switch for activating the device. As illustrated, the proximal portion 162 is electrically coupled to another portion of the face mask through a counter electrode 166. It will be appreciated, however, 15 that the counter electrode 166 may be applied to other parts of the individual's body to complete the electrical circuit. For example, the counter electrode 166 may extend about the periphery of the mask 155 in contact with the individual's skin. 20 To utilize the electrokinetic device in the form of a face mask, the user dons the mask and attaches the mask to overlie the skin surface on the face by securing straps 170 about the back of the head. It will be appreciated 25 that the substrate contains the medicament to be applied electrokinetically to the individual's face and thus lies in registration with the individual's face. Also note that the electrical conductors or electrodes 160 are closely spaced relative to one another to provide broad coverage, 30 only a small number of the electrodes 160 being illustrated for clarity. Consequently, with the face mask applied as illustrated, the user couples the distal and proximal portions 164 and 162, respectively, to one another, completing the circuit from the power source, 35 through the distal portion, the electrical conductors 160 which electrokinetically motivate the medicament into the facial skin, and the counter electrode for return to the N \Melbourne\CasCs\Patent\54000-54999\P54475 AU I \Specis\P54475.AU I Specification 2007.6-29.doc 1/08107 - 35 power source. Alternatively, the coupling of the distal and proximal portions may enable the circuit, provided an on/off switch in the circuit is turned "on". A multi channel system is provided in the face mask and 5 particulars of the multi-channel system are disclosed in U.S. Patent No. 5,160,316, issued November 3, 1992, the disclosure of which is incorporated herein by reference. In Figure 14, like parts as in Figure 13 are designated by 10 like reference numerals followed by the suffix "a". The mask 155 is abbreviated from that illustrated in Figure 13 and overlies facial regions about the eyes and nose of the individual and may cover substantially the entire forehead and portions of the cheeks or possibly include the neck or 15 be a separate specific neck treatment applicator. The electromechanical elements of the embodiment are similar to those of Figure 13 and include the underlying medicament carrying porous substrate 156a, electrical connector 158a, lead wires 160a, proximal and distal 20 portions 162a and 164a, respectively, and a counter electrode 166a. The functionality of these elements is the same as in the previous embodiment. In a further embodiment of the present invention, there is 25 illustrated with reference to Figures 15 and 16 a finger mounted electrokinetic delivery device, generally designated 200, for the self-administration of a medicament and generally in the form of a ring carried by or applied about an individual's finger, preferably the 30 index finger. Ring 200 includes a body 202. The generally ring-shaped body 202 has a through-opening 204 to receive the individual's finger and which opening is flanked by a pair of arcuate sections 206 which, together with a top portion of body 202, form a split ring for maintaining the 35 device 200 on the individual's finger. It will be appreciated, of course, that body 202 may comprise a full circular ring without interruption, although the split N \Melbourm\Cases\Patent\54000-54999\PS4475 AU I\Spccis\P54475 AU I Specification 2007-6-29 doc 1/08/07 - 36 ring form is believed preferable to provide flexibility and to accommodate different finger sizes. The device 200 is self-contained and thus includes within 5 the body 202 a power source 208 and electronics 210, as well as electrical connections 212 and 214 for electrically connecting the power source and electronics to an active electrode 216 and a counter electrode 218, respectively. The power source 208 and electronics 210 are 10 similar to those described previously in the prior embodiments. The active electrode 216 may be in the form of a disk disposed in a recess 220, preferably circular, along the flat outer surface 222 of the ring-shaped body. Overlying the active electrode 216 and in contact 15 therewith is a corresponding generally circular substrate 224 having the same attributes as the substrates 56, 156 previously described. Substrate 224 is maintained on the body 202 by a cap 226 secured to the flat outer surface 222 of the body and having marginal portions 228 overlying 20 margins of the substrate 224. As in the prior embodiments, the substrate 224 contains a unit dose of medicament, and hydration material, if necessary, pre-packaged with the device 200 for one-time disposable use. Alternatively, the substrate 224 may be separately packaged with a unit dose 25 of medicament and hydration material, if necessary, apart from device 200 and applied to the device 200 and removed therefrom for each use whereby the device 200 may be reused with successive one-time use pre-packaged substrates with medicament. As in previous embodiments, 30 the outer contact surface of the substrate which is to be applied to the treatment site may be overlaid with a foil or releasable film, e.g., as illustrated in Figure 7, to protect the contact surface and medicament prior to use. 35 The counter electrode 218 is preferably formed along the inside concave surface of the ring-shaped device 200. It will be appreciated that upon applying the ring-shaped N \Melbourne\Cases\Patent\54000-54999\P54475.AU. I\Specis\P54475.AU. I Specification 2007-6-29 doc 1/08107 - 37 body 202 to the individual's finger, the counter electrode 218 will automatically lie in electrical contact with the individual's finger. That is, the flexible side sections 206 of the device 200 bias the body 202 such that counter 5 electrode 218 is pressed against the individual's finger. As illustrated in Figure 16, the red and green LED's are indicated 230 and 232 along one side of the device to afford the indications described previously. 10 To use the device, the ring is disposed about the individual's finger. The device 200 may be provided with an on/off switch to enable the circuit between the active and counter electrodes and through the individual's body. Alternatively, the circuit may be activated in response to is application of the ring-shaped body about the individual's finger. For example, the counter electrode 218 may be movable from an outwardly exposed position within the opening 204 to a position lying flush with the interior surface of the ring-shaped body 202 and which movement 20 completes the internal circuit within the body 200 between the active and counter electrodes. With the ring mounted on an individual's finger, it will be appreciated that the substrate can be disposed over a treatment site which completes the electrical circuit through the individual's 25 body and enables electrokinetic transport of the medicament into the treatment site. At the end of the treatment period, the device may be removed from the individual's finger and discarded in its entirety. Alternatively, the device is removed from the individual's 30 finger and substrate may be removed from the ring and replaced by a fresh medicament-containing substrate for subsequent treatment. Of course, if reuse of the device with a fresh substrate is indicated, the on/off switch is placed in the "off" condition or the circuit may be 35 interrupted automatically upon removal of the device from the individual's finger and return of the counter N \Melbourne\Cases\Patent\54000-54999\P54475 AU I\Specis\P54475 AU. I Specification 2007-6.29doc 1/08/07 - 38 electrode 218 to its projecting position within the opening 204. FIGURES 17 and 18 are a bottom view and a side perspective s view, respectively, of a patch applicator 300. The patch applicator is intended for limited (one- or two-time) use, after which it is disposed. Patch applicator 300 includes an active electrode 302 and a counter electrode 304. Embedded within the applicator body 306 are a battery 308, 10 a switch 310 and an ASIC 312. Optionally, an LED may be provided. Switch 310 may be a touch-sensitive switch (e.g., membrane) so that the user's finger applied to the counter electrode 304 to hold the applicator in place at the treatment site activates the patch applicator. ASIC 15 312 controls the treatment current, treatment time, etc. as appropriate for the treatment for which the patch applicator is intended. The optional LED may be illuminated to provide a visual indication that the patch applicator is activated. Alternatively, a non-ultrasound 20 generated vibration can be added or used in lieu of the LED to indicate a working status of the device and that the device lies in a closed current loop via the individual's body surface. 25 While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiment, it is to be understood that the invention is not to be limited to the disclosed embodiment, but on the contrary, is intended to cover 30 various modifications and equivalent arrangements included within the spirit and scope of the appended claims In the claims which follow and in the preceding description of the invention, except where the context 35 requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, N \Melboumc\Cases\Patcnt\54000-54999\P54475.AU. I\Specis\P54475.AU I Specification 2007-6-29.doc 1/08/07 - 39 i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention. N \Melboume\Cases\Patent\54000-54999\P54475.AU. I\Specis\PS4475 AU I Specification 2007-6-29 doc 1/08/07